The Fact About ABBV-744 in combination with immunotherapy That No One Is Suggesting
In Section C, participants will get ABBV-744 and oral navitoclax. In Phase D, participants will get ABBV-744 and ruxolitinib. Contributors will receive treatment right until disorder progression or the members are unable to tolerate the study drugs.Feasible new approaches with the prognosis and treatment of AML. (A) The identification of super enha